PE20040122A1 - Derivados de aminometil cromano di-sustituido como agonistas de beta-3-adreno-receptores - Google Patents
Derivados de aminometil cromano di-sustituido como agonistas de beta-3-adreno-receptoresInfo
- Publication number
- PE20040122A1 PE20040122A1 PE2002000489A PE2002000489A PE20040122A1 PE 20040122 A1 PE20040122 A1 PE 20040122A1 PE 2002000489 A PE2002000489 A PE 2002000489A PE 2002000489 A PE2002000489 A PE 2002000489A PE 20040122 A1 PE20040122 A1 PE 20040122A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- hypertriglyceridemia
- nr1r1
- halo
- Prior art date
Links
- -1 DI-SUBSTITUTED AMINOMETHYL CHROMANE Chemical class 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 4
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 4
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 101150047265 COR2 gene Proteins 0.000 abstract 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical class [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 abstract 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 abstract 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A DERIVADOS CROMANOS DE FORMULA I, DONDE: R ES HIDROXI, OXO, HALO, CIANO, NITRO, ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO CON FENILO, HALOALQUILO C1-C10, CF3, NR1R1, SR1, OR1, SO2R2, ENTRE OTROS; R1 ES H, (CH2)d-O-(CH2)dR5, ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO CON HIDROXI, HALO, CO2-ALQUILO C1-C4, ENTRE OTROS; d ES 1-3; R2 ES R1, OR1, NR1R1, NHS(O)bFENILO OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS; R3 ES H, ALQUILO C1-C10, BENCILO, COR2; R4 ES H, ALQUILO C1-C10, ALQUILO C1-C10-FENILO, ALQUILO C1-C10-PIRIDINA, ENTRE OTROS; R5 ES H O COOH; Ar ES FENILO OPCIONALMENTE FUSIONADO A UN CICLOHEXILO, FENILO, HETEROCICLO DE 5-6 MIEMBROS; X ES O, S(O)b; Y ES HALO, R1, OR1, SR1, CO2R1, NR1R1, S(O)b-FENILO-CO2R1, FENILO OPCIONALMENTE FUSIONADO CON FENILO, HETEROCICLO; a ES 0-5; b ES 0-2; e ES 1-2. SON COMPUESTOS PREFERIDOS (2S)-1-({[(2R)-6-YODO-3,4-DIHIDRO-2H-CROMEN-2-IL]METIL}AMINO)-3-FENOXI-2-PROPANOL; (2S)-1-(BENCIL{[(2R)-6-BROMO-3,4-DIHIDRO-2H-CROMEN-2-IL]METIL}AMINO)-3-FENOXI-2-PROPANOL, ENTRE OTROS; TAMBIEN SE REFIERE A UN METODO PARA LA PREPARACION Y A UNA COMPOSICION FARMACEUTICA . LOS COMPUESTOS SON AGONISTAS DEL RECEPTOR BETA-3 ADRENERGICO Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DIABETES, TRASTORNOS DE LA GLUCOSA EN AYUNAS, TOLERANCIA DE LA GLUCOSA DETERIORADA, OBESIDAD, HIPERTRIGLICERIDEMIA, HIPERPLASIA PROSTATICA BENIGNA ,EFERMEDADES CARDIOVASCULARES Y ENFERMEDADES RELACIONADAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25473500P | 2000-12-11 | 2000-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040122A1 true PE20040122A1 (es) | 2004-03-10 |
Family
ID=22965389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000489A PE20040122A1 (es) | 2000-12-11 | 2002-06-07 | Derivados de aminometil cromano di-sustituido como agonistas de beta-3-adreno-receptores |
Country Status (11)
Country | Link |
---|---|
US (1) | US6699860B2 (es) |
EP (1) | EP1343778A2 (es) |
JP (1) | JP2004524286A (es) |
AR (1) | AR035605A1 (es) |
AU (1) | AU2002228816A1 (es) |
CA (1) | CA2430992A1 (es) |
HN (1) | HN2001000275A (es) |
PE (1) | PE20040122A1 (es) |
SV (1) | SV2003000756A (es) |
UY (1) | UY27065A1 (es) |
WO (1) | WO2002048134A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
WO2003072573A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
AU2003248352A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS |
US7750029B2 (en) | 2002-11-07 | 2010-07-06 | Astellas Pharma Inc. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
AU2003291012A1 (en) * | 2002-11-15 | 2004-06-15 | Galileo Pharmaceuticals, Inc. | Chroman derivatives for the reduction of inflammation symptoms |
DE10348257A1 (de) * | 2003-10-16 | 2005-05-25 | Merck Patent Gmbh | Verfahren zur Herstellung von enantiomereneinen in 2-Position substituierten Chromanderivaten |
RU2006119331A (ru) * | 2003-11-03 | 2007-12-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА, α-АНТАГОНИСТ И/ИЛИ ИНГИБИТОР 5α-РЕДУКТАЗЫ |
US20050222247A1 (en) * | 2003-12-13 | 2005-10-06 | Bayer Healthcare Ag | Chroman derivatives |
CA2618568A1 (en) * | 2005-08-18 | 2007-02-22 | F. Hoffmann-La Roche Ag | Thiazolyl piperidine derivatives useful as h3 receptor modulators |
RU2008115032A (ru) | 2005-11-03 | 2009-12-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Арилсульфонилхроманы в качестве ингибиторов 5-нт6 |
US20100029689A1 (en) * | 2008-07-02 | 2010-02-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
WO2011122524A1 (ja) | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 放出制御医薬組成物 |
US11040935B2 (en) | 2016-10-05 | 2021-06-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule AMPK activators |
JP2021042126A (ja) * | 2017-12-27 | 2021-03-18 | 佐藤製薬株式会社 | アリールオキシ化合物 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3706764A (en) | 1969-04-16 | 1972-12-19 | Yoshitomi Pharmaceutical | Phenethylaminomethyl-chromanones and- thiochromanones |
US3803176A (en) | 1969-05-09 | 1974-04-09 | Novo Terapeutisk Labor As | Sulfonylurea derivatives |
GB1499323A (en) | 1974-03-22 | 1978-02-01 | Fisons Ltd | 6-substituted chromones and chromanones |
US4474788A (en) | 1981-11-12 | 1984-10-02 | Fisons Plc | Anti-SRSA quinoline carboxylic acid derivatives |
EP0091749A3 (en) | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
ZA844519B (en) | 1983-06-24 | 1985-02-27 | Hoffmann La Roche | Dihydrobenzopyran derivatives |
US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
DE3411992A1 (de) | 1984-03-31 | 1985-10-10 | Bayer Ag, 5090 Leverkusen | Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
GB8801306D0 (en) | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
FR2695387B1 (fr) | 1992-09-09 | 1994-10-21 | Adir | Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
CA2164009A1 (en) | 1993-06-14 | 1994-12-22 | Robert L. Dow | Secondary amines as antidiabetic and antiobesity agents |
GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
US5541197A (en) | 1994-04-26 | 1996-07-30 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
US5561142A (en) | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
US5516917A (en) | 1994-06-08 | 1996-05-14 | G. D. Searle & Co. | Leukotriene B4 antagonists |
JPH08198866A (ja) | 1995-01-20 | 1996-08-06 | Tokyo Tanabe Co Ltd | 新規2−アミノ−1−フェニルエタノール化合物 |
US5663194A (en) | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
FR2746395B1 (fr) | 1996-03-22 | 1998-04-17 | Adir | Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP3708624B2 (ja) | 1996-03-27 | 2005-10-19 | キッセイ薬品工業株式会社 | 3,4−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体 |
EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
EP0906310A4 (en) | 1996-06-07 | 1999-09-01 | Merck & Co Inc | OXADIAZOLE-BENZOSULFONAMIDES AS SELECTIVE BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIS AND OBESITY |
AU728812B2 (en) | 1997-01-28 | 2001-01-18 | Merck & Co., Inc. | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity |
UA62993C2 (en) * | 1997-12-19 | 2004-01-15 | Bayer Ag | CHROMAN DERIVATIVES SUBSTITUTED ON CARBOXYLIC GROUP USED AS AGONISTS OF b-3-ADRENORECEPTOR |
US6051586A (en) * | 1997-12-19 | 2000-04-18 | Bayer Corporation | Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-12-04 AR ARP010105640A patent/AR035605A1/es unknown
- 2001-12-07 JP JP2002549665A patent/JP2004524286A/ja not_active Withdrawn
- 2001-12-07 WO PCT/US2001/046623 patent/WO2002048134A2/en not_active Application Discontinuation
- 2001-12-07 EP EP01989934A patent/EP1343778A2/en not_active Withdrawn
- 2001-12-07 US US10/008,928 patent/US6699860B2/en not_active Expired - Fee Related
- 2001-12-07 AU AU2002228816A patent/AU2002228816A1/en not_active Abandoned
- 2001-12-07 CA CA002430992A patent/CA2430992A1/en not_active Abandoned
- 2001-12-10 HN HN2001000275A patent/HN2001000275A/es unknown
- 2001-12-10 SV SV2001000756A patent/SV2003000756A/es unknown
- 2001-12-11 UY UY27065A patent/UY27065A1/es unknown
-
2002
- 2002-06-07 PE PE2002000489A patent/PE20040122A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2002048134A3 (en) | 2003-02-06 |
UY27065A1 (es) | 2002-07-31 |
US20030078258A1 (en) | 2003-04-24 |
US6699860B2 (en) | 2004-03-02 |
EP1343778A2 (en) | 2003-09-17 |
SV2003000756A (es) | 2003-01-13 |
JP2004524286A (ja) | 2004-08-12 |
AU2002228816A1 (en) | 2002-06-24 |
WO2002048134A2 (en) | 2002-06-20 |
CA2430992A1 (en) | 2002-06-20 |
AR035605A1 (es) | 2004-06-16 |
HN2001000275A (es) | 2003-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040122A1 (es) | Derivados de aminometil cromano di-sustituido como agonistas de beta-3-adreno-receptores | |
PE20021073A1 (es) | Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3 | |
UY26974A1 (es) | Agonistas del receptor beta3 adrenérgico y usos de los mismos | |
PE20070545A1 (es) | Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo como agentes moduladores de ppar, composiciones farmaceuticas que los contienen y procedimientos para su preparacion | |
PE20070108A1 (es) | Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n-[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida | |
AR058618A1 (es) | "( indazol -5- il) - pirazinas y (1,3- dihidro- indol-2- ona) - pirazinas para el tratamiento de enfermedades y afecciones mediadas por rho quinasa | |
AR104566A2 (es) | Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo | |
PE20020722A1 (es) | Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano | |
PE20040775A1 (es) | DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2 | |
PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
CL2021002651A1 (es) | Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona | |
BR0109373A (pt) | Processo para fabricação de um sal de citalopram; base cristalina de citalopram e sua composição farmacêutica | |
MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
PE20020693A1 (es) | Agonistas del receptor alfa activado del proliferador de peroxisomas | |
AR051965A1 (es) | Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida | |
PE69299A1 (es) | Compuestos calciliticos | |
PE20060988A1 (es) | Sintesis asimetrica de dihidrobenzofuranos sustituidos | |
EA200400762A1 (ru) | Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции | |
PE20080408A1 (es) | Agonistas de ep2 | |
AR047523A1 (es) | Procedimiento para la preparacion de 1-(2s,3s)-2-bencidril-n-(5-terc-butil-2-metoxibencil)quinuclidin-3-amina | |
GT199900154A (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. | |
PE20060640A1 (es) | Derivados del acido alcanoico arilcicloalquil-sustituidos y procedimientos para su preparacion | |
PE20040907A1 (es) | Derivados de anilinopirazol | |
PE20001583A1 (es) | Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina | |
PE20080984A1 (es) | Aminometil-2-imidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |